4SCAR19U T Cells Targeting B Cell Malignancies
Condition: B Cell Malignancies · Sponsor: Shenzhen Geno-Immune Medical Institute
About this study
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.
This description comes directly from the study's public registry record.
Talk to the study team
Lung-Ji Chang, Ph.D · +86 0755-86573763 · c@szgimi.org
Always discuss trial participation with your own doctor first.
Locations (1)
| Shenzhen Geno-Immune Medical Institute | Shenzhen, Guangdong, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05995015